PENNY BURCHAM: Open Payments
NPI 1609967520 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,733 in 238 payments from 35 companies in 2025. Trend: 2023 $4,382 · 2024 $4,916 · 2025 $4,733
Food & beverage: $4,733
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $444 |
| PFIZER INC. | 23 | $395 |
| UCB, Inc. | 14 | $326 |
| JAZZ PHARMACEUTICALS INC. | 13 | $286 |
| Novartis Pharmaceuticals Corporation | 20 | $272 |
| SK Life Science, Inc. | 11 | $252 |
| Lilly USA, LLC | 16 | $220 |
| ARGENX US, INC. | 8 | $183 |
| Alexion Pharmaceuticals, Inc. | 6 | $168 |
| ACADIA Pharmaceuticals Inc | 8 | $166 |
Products named: NURTEC ODT, KESIMPTA, XYWAV, Nayzilam, QULIPTA, VYVGART HYTRULO, ULTOMIRIS, NUPLAZID.
Industry payments across MS — which companies pay providers there.
